[March 14, 2014]

Research and Markets: Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies

Research and Markets (http://www.researchandmarkets.com/research/f99r79/competitor) has announced the addition of the "Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies" report to their offering.

The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of March 2014.

Marketed antibodies are attractive for companies to create next generation variants and biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules.

Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 75.7 bln in the year 2013. Cumulated 2013 sales of branded therapeutic antibodies approaching patent expiry and, therefore, target of biosimilar substitution, reached US$ 58.6 bln.

The report lists specifically for each target the branded products with their 2013 sales and up-side indications in development, as well as follower, biosuperior and biosimilar antibody drug candidates in development.

2013 Sles data are provided for

- Rituxan/MabThera

- Arzerra

- Zevalin

- Gazyva

- Herceptin

- Perjeta

- Kadcyla

- Avastin

- Zaltrap

- Erbitux

- Vectibix

- XGEVA

- Yervoy

- Adcetris

- Poteligeo

- Humira

- Enbrel

- Remicade

- Simponi

- Cimzia

- Orencia

- Nulojix

- Ilaris

- Arcalyst

- Tysabri

- Soliris

- Xolair

- Stelara

- Actemra/RoActemra

- Benlysta

- Lemtrada

- ReoPro

- Nplate

- Prolia

- Lucentis

- Eylea

- Synagis

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior antibodies against commercially and clinically validated targets. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,

- Target (News - Alert) / Mechanism of Action,

- Class of Compound,

- Company,

- Product Category,

- Indication,

- R&D Stage and

- additional comments with a hyperlink leading to the source of information.

Key Topics Covered

1. 2013 Sales of Recombinant Therapeutic Antibodies

2. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors

3. Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors

4. VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

5. EGF-R Antibodies -Biosimilars and Biosuperiors

6. TNF Antibodies -Biosimilars and Biosuperiors

7. IgE Antibodies: Xolair, Biosuperiors & Biosimilars

8. Interleukin-6 Receptor (IL-6R) Antibodies: Actemra, Biosuperiors & Biosimilars

9. GPIIb/IIIa Antibodies: ReoPro, Biosuperiors & Biosimilars

10. CD52 Antibodies: Lemtrada, Biosuperiors & Biosimilars

11. Apha4/beta1/7 Antibodies: Tysabri, Biosuperiors & Biosimilars

12. Complement C5 Antibodies: Soliris, Biosuperiors & Biosimilars

13. Respiratory Syncytial Virus (RSV): Synagis, Biosuperiors & Biosimilars

14. RANKL Antibodies: Prolia/XGEVA, Biosuperiors & Biosimilars

15. CD80/86 (B7-1/B7-2) Antibodies: Orencia; Nulojix, Biosuperiors & Biosimilars

16. Interleukin-12/-23 Antibodies: Stelara, Biosuperiors & Biosimilars

17. Corporate Biosimilar and Biosuperior Therapeutic Antibody Pipelines

For more information visit http://www.researchandmarkets.com/research/f99r79/competitor

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

[ Back To TMCnet.com's Homepage ]